What Is the Impact of Bleeding After Acute MI Treatment?

A large, observational study indicates that the risk for both in-hospital and 6-month mortality is significantly increased in patients with major bleeding.

Several randomized studies have documented an association between bleeding after acute MI treatment and adverse events. Using data on 40,087 acute MI patients (53% ST-segment-elevation MI [STEMI], 47% non-STEMI) from the large, multicenter Global Registry of Acute Coronary Events (GRACE), investigators sought to determine whether (and if so, how) bleeding is associated with outcomes in a population-based cohort.

Among the study population, 1140 patients (2.8%) had major in-hospital bleeding at a vascular access (29%), intracerebral (6%), or other (53%) site. Among these patients, 57% received blood transfusions of ≥2 units. At 6 months, mortality was 25.7% in patients with major bleeding versus 9.3% in those without major bleeding (P<0.001).…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)